ArticleTransboundary and emerging diseases2025
The Functional DPP4 Receptor Is an Indispensable Factor Mediating the Immune Performance of Mucosal Vaccines for Middle East Respiratory Syndrome.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal vaccines are powerful tools for combatting emerging infectious diseases, particularly mucosal-associated pathogens. However, one of the main bottlenecks in developing mucosal vaccines is the lack of accurate animal models. In this study, a vesicular stomatitis virus (VSV)-vectored Middle East respiratory syndrome coronavirus (MERS-CoV) mucosal vaccine was designed for investigations. Compared with the VSV backbone, rVSVΔG-MERS-S exhibited altered cellular tropism, as determined by MERS-S. In wild-type (WT) C57BL-6J mice and hamsters, the nasal spray of rVSVΔG-MERS-S was poorly immunogenic. In contrast, rVSVΔG-MERS-S was highly immunogenic in transgenic mice (hDPP4 mice) and hDPP4-transduced hamsters harboring the functional MERS-CoV receptor. Compared with those of WT C57BL-6J mice, the nasal spray of rVSVΔG-MERS-S resulted in effective antigen-presenting cell (APC) priming, Tfh-GcB-plasma cell (pC) proliferation, and robust humoral and cellular responses, together with the activation of antiviral signaling pathways in hDPP4 mice. Similarly, rVSVΔG-MERS-S was highly immunogenic in alpacas and rhesus monkeys, which are naturally susceptible to MERS-CoV and harbor the effective DPP4 receptor. The alignment of hDPP4 receptors in these animals revealed that L294, I295, and R336 in DPP4 are key residues contributing to differences in sensitivity across species. Consistently, a high binding affinity was observed between human, alpacas, and rhesus monkey DPP4 receptors and MERS-CoV receptor binding domains (RBDs) compared with that of mice and hamster. Overall, this proof-of-concept study not only guides the selection of appropriate animal models for the evaluation of mucosal vaccines of MERS but also provides evidence that functional receptors DPP4 in animal models are prerequisites for the immune performance of the MERS mucosal vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.